Share on StockTwits

Investment analysts at S&P Equity Research lifted their price target on shares of Cepheid (NASDAQ:CPHD) from $6.58 to $8.30 in a note issued to investors on Monday. The firm currently has a “hold” rating on the stock. S&P Equity Research’s price objective would suggest a potential downside of 78.55% from the stock’s current price.

Cepheid (NASDAQ:CPHD) traded up 1.63% on Monday, hitting $39.33. The stock had a trading volume of 252,490 shares. Cepheid has a 1-year low of $34.42 and a 1-year high of $55.89. The stock has a 50-day moving average of $44.24 and a 200-day moving average of $47.21. The company’s market cap is $2.761 billion.

Cepheid (NASDAQ:CPHD) last announced its earnings results on Thursday, July 17th. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.16. The company had revenue of $116.50 million for the quarter, compared to the consensus estimate of $115.47 million. During the same quarter last year, the company posted $0.02 earnings per share. Cepheid’s revenue was up 21.4% compared to the same quarter last year. Analysts expect that Cepheid will post $-0.52 EPS for the current fiscal year.

CPHD has been the subject of a number of other recent research reports. Analysts at ISI Group upgraded shares of Cepheid from a “sell” rating to a “neutral” rating in a research note on Monday. They now have a $38.50 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Cepheid in a research note on Friday. They now have a $41.00 price target on the stock. Finally, analysts at Raymond James reiterated an “outperform” rating on shares of Cepheid in a research note on Friday, July 18th. They now have a $54.00 price target on the stock, down previously from $57.00. Nine research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $48.32.

Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.